Patient-Derived Organoid Drug Responses for KRAS-Mutant Pancreatic Cancer

A preclinical dataset from a study establishing a biobank of 66 patient-derived pancreatic cancer organoids and xenografts. The data includes results from next-generation sequencing of 425 oncogenes and in vitro screening against 32 drugs, evaluating synergistic combinations like trametinib/AZD8055. The dataset was created by Xiaorui Wang and last updated on May 15, 2026.

Use Cases

• Identify synergistic drug combinations for KRAS-mutant cancers based on the described MEK/mTOR inhibitor screening.
• Validate patient-derived organoid models as predictive tools for clinical chemotherapy responses based on the gemcitabine/paclitaxel validation.
• Analyze genetic heterogeneity in pancreatic cancer based on the next-generation sequencing of 425 oncogenes.
• Benchmark in vitro drug screening results against in vivo xenograft models based on the study's validation approach.

Strengths

• Includes data from a biobank of 66 patient samples with 69% organoid and 31% xenograft success rates.
• Drug response data is validated across in vitro organoid and in vivo xenograft models for consistency.
• Sequencing covers a panel of 425 oncogenes, providing a detailed genetic profile.

Limitations

• Description metadata is limited; actual data quality requires manual inspection after download.
• The study notes limitations such as a small sample size and lack of tumor microenvironment components in the models.
• Column-level documentation is absent; field semantics must be inferred after download.

Provenance

Source

figshare

Collection Method

Data generated from establishing a patient-derived organoid/xenograft biobank, next-generation sequencing, and high-throughput drug screening.

Freshness

Last updated 2026-05-15 04:21:47; freshness should be verified.